Clinical trials
A newly developed radiopharmaceutical composition, created by inventors Jalomaki and Seppanen, has shown significant promise in treating prostate cancer with lower rates of toxicity. The composition, which targets prostate-specific membrane antigen (PSMA), has been designed to provide a safer and more effective treatment option for patients with metastatic castration-resistant prostate
Cancer research
Experts at The Institute of Cancer Research, London, are urging men with BRCA1 and BRCA2 gene mutations to undergo annual prostate cancer screening, citing evidence that targeted PSA testing can pick up more aggressive cancers at a younger age. The recommendation comes after five years of data from the international
Cancer research
Men with BRCA1 and BRCA2 gene mutations face a significantly higher risk of aggressive prostate cancer, according to a new study published in the European Society for Medical Oncology (ESMO) Congress in Berlin. The study, funded by Cancer Research UK, the Institute of Cancer Research (ICR), and others, found that
Cancer research
Researchers at Gifu University Graduate School of Medicine have made a significant breakthrough in the treatment of prostate cancer, particularly in cases of metastatic castration-sensitive prostate cancer (mCSPC). A recent study published in Cancer Reports has demonstrated the efficacy of a combination therapy involving androgen receptor signaling inhibitors, denosumab, and
Cancer research
Prostate cancer patients with intermediate-to-high-risk disease treated with external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) often experience biochemical recurrence (BCR). New research from the National Cancer Institute (NCI) has identified TGF-b activity as a dominant feature of these tumors, potentially serving as an independent prognostic biomarker for BCR.
Cancer research
French researchers have made a significant breakthrough in the treatment of prostate cancer by discovering that inhibiting histone H4-lysine 20 (H4K20) methyltransferases SUV4-20H1 and SUV4-20H2 can induce synthetic lethality in combination with the topoisomerase II poison etoposide. This epigenetic therapy targets the SUV4-20H enzymes, which play a crucial role in
Cancer treatment
Research presented in a recent narrative review has shed light on the effectiveness of ultrahypofractionated radiotherapy in treating localized prostate cancer. The study compared single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy, highlighting the potential benefits of these ultra-hypofractionated strategies in delivering high-precision ablative
Cancer research
Researchers from Guangdong Medical University have developed a prognostic signature consisting of fatty acid metabolism genes using machine learning algorithms to predict biochemical recurrence and aid in androgen receptor signaling inhibitors (ARSI) therapy in prostate cancer patients. The study's findings suggest that the FAM-related gene score (FAMRGs) can
Cancer research
Researchers at the University of Nebraska Medical Center have made a significant discovery in the field of oncology, unveiling a novel androgen receptor target gene called ECD that plays a pivotal role in promoting prostate cancer tumorigenesis by regulating glycolysis. The study, published in the journal Oncogene, highlights the critical
Cancer research
Researchers at the Medical University of Sofia have conducted a multicenter, retrospective study to evaluate the predictive value of mutations in effector genes versus sensor genes in patients with metastatic castration-resistant prostate cancer (mCRPC) classified as homologous recombination deficiency (HRD)-positive. The study found that patients with effector mutations in
Cancer research
Organ transplant recipients in the United States have a lower risk of developing breast and prostate cancers compared to the general population. To explore this observation, researchers conducted a case-control study using the SEER-Medicare database, examining US adults aged 65 years or older. The study found that solid organ transplant
Cancer research
A new study on the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has highlighted the evolving landscape of clinical trial evidence and real-world practice. The researchers, from Bayer HealthCare, conducted a retrospective study using administrative claims data in the Komodo Research Dataset from January 2016 to September 2023. The study
